Expression profiles and prognostic value of miRNAs in retinoblastoma

J Cancer Res Clin Oncol. 2019 Jan;145(1):1-10. doi: 10.1007/s00432-018-2773-7. Epub 2018 Oct 22.

Abstract

Current cure rates for retinoblastoma (RB) are very high in developed countries. Nonetheless, in less privileged places worldwide, delayed diagnosis and refusal to adhere to treatment still endure an obstacle to improve overall patient survival. Thus, the access to consistent biomarkers for diagnosis at an earlier stage may facilitate treatment and improve outcomes. Over recent years, much attention has been focused on miRNAs, key post-transcriptional regulators that when altered, largely contribute to carcinogenesis and tumor progression. Many of the ~ 2500 microRNAs described in humans have shown differential expression profiles in tumors. In this review, we summarize current data about the roles of miRNAs in RB along with their value as diagnostic/prognostic factors using electronic databases such as PubMed. We reviewed the importance of miRNA in RB biology and discussed their implications in clinic intervention. Several miRNAs have pointed out reliable diagnostic and prognostic molecular biomarkers. The emergence of targeted therapies has significantly improved cancer treatment. In the near future, the modulation of miRNAs will represent a good treatment strategy.

Keywords: Cancer; Children; Retinoblastoma; Review; Solid tumor; miRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Gene Expression Profiling*
  • Humans
  • MicroRNAs / biosynthesis
  • MicroRNAs / genetics*
  • Prognosis
  • Retinal Neoplasms / genetics*
  • Retinal Neoplasms / pathology
  • Retinoblastoma / genetics*
  • Retinoblastoma / pathology
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • MicroRNAs